玻璃体内注射地塞米松植入物治疗糖尿病性黄斑水肿的疗效与安全性
Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema.
作者信息
Guigou Sebastien, Pommier Stephan, Meyer Franck, Hajjar Christian, Merite Pierre Yves, Parrat Eric, Rouhette Herve, Rebollo Olivier, Matonti Frederic
机构信息
P1.5 Network, Mougins, France.
出版信息
Ophthalmologica. 2015;233(3-4):169-75. doi: 10.1159/000381356. Epub 2015 Apr 22.
PURPOSE
To evaluate the efficacy and safety of intravitreal implant of dexamethasone (Ozurdex®) in diabetic macular edema (DME).
METHODS
This was a retrospective multicenter noncomparative study. Seventy-eight patients with DME followed for at least 6 months were included (P1.5 Network). Best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP) and cataract progression were studied at baseline and then at 1, 2, 4 and 6 months.
RESULTS
The mean CRT decrease from baseline was 145.2 µm at 6 months. The mean BCVA improvement from baseline was 6.7 at 6 months. An increase in IOP was observed for 11.7% of patients, and all patients were managed by topical treatment. No glaucoma or cataract surgery was necessary, and no endophthalmitis was reported.
CONCLUSIONS
One injection of Ozurdex has an anatomical and functional effectiveness for the treatment of DME. Side effects were rare and manageable in our practice. © 2015 S. Karger AG, Basel.
目的
评估玻璃体内植入地塞米松（Ozurdex®）治疗糖尿病性黄斑水肿（DME）的疗效和安全性。
方法
这是一项回顾性多中心非对照研究。纳入了78例随访至少6个月的DME患者（P1.5网络）。在基线时以及之后的1、2、4和6个月研究最佳矫正视力（BCVA）、中心视网膜厚度（CRT）、眼压（IOP）和白内障进展情况。
结果
6个月时CRT较基线平均下降145.2 µm。6个月时BCVA较基线平均提高6.7。11.7%的患者眼压升高，所有患者均通过局部治疗处理。无需进行青光眼或白内障手术，且未报告眼内炎。
结论
一次注射Ozurdex对DME的治疗具有解剖学和功能上的有效性。在我们的实践中，副作用罕见且可控制。© 2015 S. Karger AG，巴塞尔。
Zotero 插件